TCTMD

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Experts emphasized that obesity is a chronic, relapsing condition and lifelong therapy—in some form—will be necessary.
Le Lézard

Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling Development to Address Long-Term Obesity Management

Incregen Therapeutics Advances First-in-Class GIP Ligand Antagonist INC-118 into IND-Enabling Development to Address Long-Term Obesity Management INC-118 directly antagonizes the circulating Glucose ...
PharmExec

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...
Fierce Biotech

Equipped with $160M series A, Alveus debuts into crowded obesity development landscape

Looking to overcome some of the limitations of existing obesity drugs, Alveus Therapeutics has debuted with nearly $160 ...
The Malaysian Reserve

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight ...

Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 ...
News-Medical.Net on MSN

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and ...